Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Tamas Szuts

Istvan Hermecz

Agnes Horvath

Gabor Kovacs

Sandor Virag

Gyula Sebestyen

Judit Sipos

Maria Balogh

Peter Ritli

Aniko Pajor

Jozsef Lengyel

Lelle V Vasvari Nee Debreczy

Peter Szentmiklosi

Geza Kereszturi

Zoltan Meszaros

Katalin Marmarosi Nee Kellner

Tibor Breining

Vera Gergely

Katalin Kaloy

Agnes Stadler Nee Szoke

Zoltan Vargay

Viktor Weiszfeiler

Jozsef Szejtli

Attila Mandi

Dezso Korbonits

Pal Kiss

Andras Szego

Gabor Nagy

Gergely Heja

Endre Palosi

Katalin Marmarosi

Gabor Horvath

Ida Szvoboda Nee Kanzel

Gyorgy Hidasi

Csaba Gonczi

Maria Szomor Nee Wundele

Jozsef Kokosi

Jeno Marton

Judit Kun

Gyorgy Szasz

Karoly Lapis

Josef Szejtli

Emil Minker

Jozsef Nemes

Kalman Magyar

Janos Feher

Janos Pinter

Maria Hornyak

Jozsef Schawartz

Peter Sarkozi

Lelle Vasvari, Nee Debreczy

Katalin Kalloy

Lelle Vasvavi

Istvan Juhasz

Geza Keresturi

Lelle V Debreczy

Gabriella Szabo Nee Ujhelyi

Szabo Anna Z

Antal Toth

Anna Szekely

Eniko Schreiner Nee Kovats

Lelle Vasvari Nee Debreczi

Erzsebet Babos Nee Vajas

Istvan Bitteer

Geza Kerszturi

An anhydrous transdermal composition is disclosed comprising in a 20 to 100% lyotropic liquid crystalline arrangement:

Transdermal compositions

The invention relates to a new process for the preparation of compounds of the Formula I ##STR1## (wherein R stands for hydrogen or methyl) and pharmaceutically acceptable salts thereof which comprises reacting a compound of the Formula V ##STR2## (wherein R.sup.1 and R.sup.2 stand for an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen: or for an aromatic acyloxy group comprising 7-11 carbon atoms) with an amine of the Formula VI ##STR3## (wherein R has the same meaning as stated above) or a salt thereof and subjecting the compound of the Formula VII ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) to hydrolysis after or without isolation and if desired converting the compound of the Formula I thus obtained into a salt thereof or setting free the same from its salt. The compounds of the Formula I are known antibacterial agents.

Process for the preparation of quinoline carboxylic acids

A method of using a compound of the Formula (V) ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, wherein R.sup.1 and R.sup.2 are each C.sub.1 to C.sub.6 aliphatic acyloxy, unsubstituted or substituted by halogen, or are each C.sub.7 to C.sub.11 aromatic acyloxy, for preventing amination of the 6-position when a compound of the Formula (I) ##STR2## or a pharmaceutically acceptable salt thereof is to be formed, which comprises the steps of:

Process for the preparation of quinoline carboxyolic acids

The invention relates to novel stable aqueous primycin solutions containing 0.5 to 1.75% by mass/volume of primycin sulfate or 2.5 to 9% by mass/volume of a complex of primycin N-methylpyrrolidone and 2 to 15% by mass/volume of pyroglutamic acid, preferably L-pyroglutamic acid or a soluble salt, preferably the sodium salt thereof as calculated for the volume of the solution to be prepared and 40 to 60% by volume of isopropanol as calculated for the volume of the solution to be prepared as well as water in an amount adding up to 100%. The stable, aqueous primycin solutions are topical antibiotics.

Stable aqueous solutions of prymicin and pharmaceutical and cosmetic

This invention relates to a primycin-containing colloidal basic gel comprising 5-30% of primycin and 95-70% of N-methyl-pyrrolidone-2. The invention also relates to antibacterial compositions particularly for the treatment of acne vulgaris comprising as active ingredient 0.1-100% of a primycin-containing colloidal basic gel, if desired together with further antimicrobial active ingredients, in admixture with 99.9-0% of usual inert pharmaceutical filling, diluting and other formulating additives. The invention also relates to combination composition comprising as active ingredient 1-60% of a primycin-containing colloidal basic gel and 0.1-40% of further pharmaceutical active ingredient(s), e.g. one or more antibiotic(s), chemotherapeutical agent(s), fungistatic or fungicidal agent(s), steroidal or non-steroidal antiinflammatory agent (s), epithelogenic agent(s), local anaesthetic(s), and/or vitamin(s).

Primycin-containing colloidal basic gel

The invention relates to the inclusion complexes of 7-isopropoxy-isoflavon formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.

Inclusion complex of 7-isopropoxy-isoflavon formed with cyclodextrin,

The invention relates to a new process for the preparation of compounds of the Formula I ##STR1## (wherein R stands for hydrogen or methyl) and pharmaceutically acceptable salts thereof which comprises reacting a compound of the Formula V ##STR2## (wherein R.sup.1 and R.sup.2 stand for an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen; or for an aromatic acyloxy group comprising 7-11 carbon atoms) with an amine of the Formula VI ##STR3## (wherein R has the same meaning as stated above) or a salt thereof and subjecting the compound of the Formula VII ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) to hydrolysis after or without isolation and if desired converting the compound of the Formula I thus obtained into a salt thereof or setting free the same from its salt. The compounds of the Formula I are known antibacterial agents. The advantage of the process of the present invention is that it makes the desired compounds of the Formula I available in a simple manner, with high yields and in a short reaction time.

1-Methylamino-quinoline-carboxylic acid derivatives

The invention relates to the inclusion complexes of 7-isopropoxy-isoflavone formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.

N,N,N-trimethyl-2-hydroxyethyl-ammonium-[1-ethyl-6-fluoro-4-oxo-7-(1-pipera zinyl)-1,4-dihydro-quinolizine-3-carboxylate] of the formula I ##STR1## as a norfloxacin antimicrobial salt capable of enteral administration.

Medicinal norfloxacin salts

The present invention relates to synergistic pharmaceutical compositions for the treatment of liver disorders comprising 5-aminoimidazole-4-carboxamide orthophosphate (AICA-phosphate) as active ingredient in association with vitamins, preferably with vitamin B and/or E and optionally with other pharmaceutical excipients.

Synergistic pharmaceutical compositions

Antitussive compounds of the formula I ##STR1## or physiologically acceptable acid addition salts thereof are disclosed, where A stands for straight or branched chain C.sub.1-5 alkylene or ##STR2## R.sub.1 stands for straight or branched chain C.sub.1-10 alkyl, halogenoalkyl, hydroxyalkyl, C.sub.5-6 cycloalkyl, vinyl, 2-ethoxyethyl, carbonylalkyl or aminoalkyl of the formula ##STR3## wherein R stands for hydrogen or methyl, n is 0 to 3,

Theophyllinyl-alkyl-oxadiazoles, process for the preparation thereof and

New Rutecarpine analogs are disclosed having Rutecarpine-like activity, especially diuretic activity. Also a novel process for the preparation of the Rutecarpine analogs is disclosed.

Indolo[2',3';3,4]pyrido[2,1-b]quinazoline-5-ones, a process for the

Antiallergic and antiasthmatic compounds of the formula ##STR1## of which 9-phenylamino-6-methyl-4-oxo-6,7-dihydro-4H-pyrido(1,2-a)pyrimidine-3-carb oxylic acid and optically active antipodes and salts thereof are examples.

Antiallergic nitrogen bridge-head compounds

Growing community of inventors

Budapest, Hungary

Tamas Szuts